about
Albumin for end-stage liver diseaseHuman Parvovirus B19 and blood product safety: a tale of twenty years of improvementsNovel parvovirus and related variant in human plasma.Distinctive Acellular Lipid Emboli in Hemoglobin SC Disease following Bone Marrow Infarction with Parvovirus InfectionCharacterization of Markers of the Progression of Human Parvovirus B19 Infection in Virus DNA-Positive Plasma SamplesExistence of various human parvovirus B19 genotypes in Chinese plasma pools: genotype 1, genotype 3, putative intergenotypic recombinant variants and new genotypes.A review of the use of human albumin in burn patients.Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals.Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses.An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.Virus inactivation and protein recovery in a novel ultraviolet-C reactor.Inactivation and neutralization of parvovirus B19 Genotype 3.Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.[Seroprevalence of rubella virus, varicella zoster virus, cytomegalovirus and parvovirus B19 among pregnant women in the Sousse region, Tunisia].Different susceptibility of B19 virus and mice minute virus to low pH treatment.Parvovirus B19 in the Context of Hematopoietic Stem Cell Transplantation: Evaluating Cell Donors and Recipients.Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins.
P2860
Q26999804-92CCB80A-CEFD-4BAF-A741-F1C581E4F273Q28087734-3D762791-2A75-4F9C-B1F3-6B392BF12CACQ35793781-67D3D751-0BEE-48F3-AC9D-E1AB61B03E88Q36043496-AEF6BA7F-780B-44DA-ABA3-64B07171D4E0Q36058219-3C593DE7-58E4-4508-83BC-D3734E94FFF5Q37263290-51E06CDF-EA6D-4B33-94D8-2BF1F11CB455Q38059163-B7D1572D-245D-4A01-A6AC-EC71543A9665Q38432271-8B042812-8358-4B5B-A185-E9E9CC264C1EQ40078515-814A8616-AD71-4052-B403-249761E041F2Q40524183-8FB620A7-6752-4E81-B780-7F0DC6ABD4A3Q40555863-6A5F5EA4-59EF-4B06-9190-813677AC12EEQ44659453-ED8B3FCC-0AD9-49AB-807E-F3A50A18631BQ44807693-C369DCBA-E025-4E74-9ECC-0E921FA54341Q45172983-A59669BF-4F51-4CE9-A6C1-234B45A9F2BBQ45620572-2CDA040F-70E1-4DAE-8960-3740C7C9ABC9Q47147160-320DE470-894E-404C-A0B3-4350FA737B88Q52016510-F7D1F259-E4E8-480A-A6F7-D8685D19DF7B
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Parvoviruses and blood products.
@ast
Parvoviruses and blood products.
@en
Parvoviruses and blood products.
@nl
type
label
Parvoviruses and blood products.
@ast
Parvoviruses and blood products.
@en
Parvoviruses and blood products.
@nl
prefLabel
Parvoviruses and blood products.
@ast
Parvoviruses and blood products.
@en
Parvoviruses and blood products.
@nl
P1476
Parvoviruses and blood products.
@en
P2093
Paul Strengers
P304
P356
10.1016/S0369-8114(02)00303-6
P577
2002-06-01T00:00:00Z